mifepristone has been researched along with Skin Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cotsarelis, G; Digiovanni, J; Kataoka, K; Kiguchi, K; Kim, DJ; Rao, D | 1 |
| Fang, X; Li, J; Zhang, X; Zhou, M | 1 |
| Alexander, CL; Greenhalgh, DA; Porter, MJ; Quinn, JA; Wu, H; Yao, D | 1 |
| Alexander, CL; Chan, WC; Greenhalgh, DA; Quinn, JA; Wu, H; Yao, D | 1 |
4 other study(ies) available for mifepristone and Skin Neoplasms
| Article | Year |
|---|---|
Targeted disruption of stat3 reveals a major role for follicular stem cells in skin tumor initiation.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Apoptosis; Cell Transformation, Neoplastic; Genes, ras; Keratinocytes; Mice; Mice, Transgenic; Mifepristone; Mutation; Skin Neoplasms; STAT3 Transcription Factor; Stem Cells | 2009 |
Effects of progesterone on the growth regulation in classical progesterone receptor-negative malignant melanoma cells.
Topics: Butadienes; Cell Line, Tumor; Cell Proliferation; Humans; Melanoma; Mifepristone; Mitogen-Activated Protein Kinase Kinases; Nitriles; Progesterone; Receptors, Progesterone; Signal Transduction; Skin Neoplasms | 2010 |
PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways.
Topics: Animals; Carcinogens; Cell Differentiation; Cell Transformation, Neoplastic; Keratin-13; Keratins; MAP Kinase Signaling System; Mice; Mice, Transgenic; Mifepristone; Oncogene Protein v-akt; Papilloma; PTEN Phosphohydrolase; ras Proteins; Skin Neoplasms; Tetradecanoylphorbol Acetate; Up-Regulation | 2006 |
Fos cooperation with PTEN loss elicits keratoacanthoma not carcinoma, owing to p53/p21 WAF-induced differentiation triggered by GSK3beta inactivation and reduced AKT activity.
Topics: Animals; Cyclin D; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Disease Progression; Keratinocytes; Keratoacanthoma; Mice; Mifepristone; Oncogene Protein v-akt; Oncogene Proteins v-fos; PTEN Phosphohydrolase; Repressor Proteins; Skin Neoplasms; Tumor Suppressor Protein p53 | 2008 |